AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33196797 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI screening only (group 2)
Number of subjects: 28641
Study 33196797 — intervention group
Group type: COMPARATOR
Intervention: Control (group 3)
Number of subjects: 28641
Study 32404059 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention (up to three in-home visits, monthly group wellness program, monthly case conferencing, care coordination)
Number of subjects: 132
Study 32404059 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention
Number of subjects: 132
Study 32404059 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 132
Study 35049029 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful parenting training (8 sessions of 90 minutes each)
Number of subjects: 24
Study 35049029 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study 34915884 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-item Altarum Consumer Engagement Measure™ (ACE Measure) - Commitment subscale
Number of subjects: 400
Study 34915884 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-item Altarum Consumer Engagement Measure™ (ACE Measure) - Navigation subscale
Number of subjects: 400
Study 33232714 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat graft
Number of subjects: 24
Study 33232714 — intervention group
Group type: COMPARATOR
Intervention: Gelatin sponge
Number of subjects: 24
Study 34559090 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 10 mg daily for 10 days, then 20 mg daily for 21 days
Number of subjects: 60
Study 34559090 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same shape and size as memantine tablets)
Number of subjects: 60
Study 32491932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib in combination with atezolizumab
Number of subjects: 0
Study 32491932 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 0
Study 36251140 — intervention group
Group type: EXPERIMENTAL
Intervention: Naoxintong Capsule (1.2 g orally, twice a day)
Number of subjects: 2200
Study 36251140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2200
Study 34174848 — intervention group
Group type: EXPERIMENTAL
Intervention: MYL‐1501D
Number of subjects: 1118
Study 34174848 — intervention group
Group type: COMPARATOR
Intervention: Reference insulin glargine
Number of subjects: 1118
Study 35538185 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg
Number of subjects: 306
Study 35538185 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg
Number of subjects: 306
Study 35538185 — intervention group
Group type: COMPARATOR
Intervention: NSAID
Number of subjects: 306
Study 35538185 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab
Number of subjects: 306
Study 35538185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 33420602 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian extract (530 mg for 30 nights)
Number of subjects: 72
Study 33420602 — intervention group
Group type: COMPARATOR
Intervention: Placebo (530 mg for 30 nights)
Number of subjects: 72
Study 34029279 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-friendly reports
Number of subjects: 300
Study 34029279 — intervention group
Group type: COMPARATOR
Intervention: Traditional reports
Number of subjects: 300
Study 32267059 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial coils treatment
Number of subjects: 78
Study 34420884 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous cholecystostomy tube (PCT)
Number of subjects: 13283
Study 34420884 — intervention group
Group type: COMPARATOR
Intervention: Cholecystectomy
Number of subjects: 13283
Study 34420884 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompensated cirrhosis
Number of subjects: 13283
Study 34420884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhosis (compensated and decompensated)
Number of subjects: 13283
Study 34326642 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 113
Study 34326642 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine + CBT
Number of subjects: 113
Study 34326642 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine + Bupropion
Number of subjects: 113
Study 34326642 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine + Bupropion + Brain Stimulation
Number of subjects: 113
Study 34326642 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 113
Study 32896498 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF therapy
Number of subjects: 24
Study 32443981 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation (CR) plus Aerobic Exercise (EX)
Number of subjects: 360
Study 32443981 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Rehabilitation (CR) plus Sham Exercise
Number of subjects: 360
Study 32443981 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Rehabilitation Sham plus Aerobic Exercise (EX)
Number of subjects: 360
Study 32443981 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Rehabilitation Sham plus Sham Exercise
Number of subjects: 360
Study 33954859 — intervention group
Group type: COMPARATOR
Intervention: 0.01% atropine (SA group)
Number of subjects: 67
Study 33954859 — intervention group
Group type: COMPARATOR
Intervention: Orthokeratology (OK group)
Number of subjects: 67
Study 33954859 — intervention group
Group type: COMPARATOR
Intervention: Combination of orthokeratology and 0.01% atropine (OKA group)
Number of subjects: 67
Study 32526153 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle trainer device
Number of subjects: 113
Study 32526153 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 113
Study 34213808 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Number of subjects: 19
Study 34213808 — intervention group
Group type: COMPARATOR
Intervention: Full ablative CO2 laser
Number of subjects: 19
Study 33775558 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 488
Study 33775558 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab + Tremelimumab
Number of subjects: 488
Study 32353536 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral-Domain OCT (SD OCT)
Number of subjects: 1094
Study 32353536 — intervention group
Group type: COMPARATOR
Intervention: Fluorescein Angiography (FFA)
Number of subjects: 1094
Study 35918097 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment
Number of subjects: 73388
Study 35918097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73388
Study 32756204 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high-flow (NHF) therapy with room air only and no supplemental oxygen
Number of subjects: 0
Study 32756204 — intervention group
Group type: COMPARATOR
Intervention: No respiratory support
Number of subjects: 0
Study 32756204 — intervention group
Group type: COMPARATOR
Intervention: Face mask oxygen administration
Number of subjects: 0
Study 32756204 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing without performing respiratory support
Number of subjects: 0
Study 33788453 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Neimadian-point plus analgesia pump (normal saline)
Number of subjects: 140
Study 33788453 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil patient-controlled intravenous analgesia plus sham EA (without stimulation)
Number of subjects: 140
Study 36345847 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehearsal expressive writing
Number of subjects: 100
Study 36345847 — intervention group
Group type: EXPERIMENTAL
Intervention: Replay expressive writing
Number of subjects: 100
Study 36345847 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 100
Study 36345847 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups measured for psychological adjustment (MHI), self-perceived stress, depression and anxiety symptoms, and self-blame
Number of subjects: 100
Study 32173050 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid showing benefits and harms of screening
Number of subjects: 400
Study 32173050 — intervention group
Group type: COMPARATOR
Intervention: Standard brochure recommending participation in screening
Number of subjects: 400
Study 33079803 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 S's infant calming technique
Number of subjects: 250
Study 33079803 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 250
Study 35358455 — intervention group
Group type: EXPERIMENTAL
Intervention: Anetumab ravtansine (6.5 mg/kg on day 1 of each 21-day cycle)
Number of subjects: 248
Study 35358455 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine (30 mg/m2 once every week)
Number of subjects: 248
Study 35358455 — intervention group
Group type: EXPERIMENTAL
Intervention: Anetumab ravtansine
Number of subjects: 248
Study 35358455 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine
Number of subjects: 248
Study 33637926 — intervention group
Group type: EXPERIMENTAL
Intervention: Scale and Polish (S&P) 6-monthly
Number of subjects: 1327
Study 33637926 — intervention group
Group type: EXPERIMENTAL
Intervention: Scale and Polish (S&P) 12-monthly
Number of subjects: 1327
Study 33637926 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised Oral Hygiene Advice (OHA)
Number of subjects: 1327
Study 33637926 — intervention group
Group type: COMPARATOR
Intervention: Usual Oral Hygiene Advice (OHA)
Number of subjects: 1327
Study 32026250 — intervention group
Group type: EXPERIMENTAL
Intervention: Short intervention discussing violence and power with women receiving HIV testing services; included training and support for HIV counselors, a take-home card for clients, and an on-site IPV counselor.
Number of subjects: 688
Study 36103212 — intervention group
Group type: EXPERIMENTAL
Intervention: High dosing grape seed flour (GSF ≈ 1 g/kg)
Number of subjects: 40
Study 36103212 — intervention group
Group type: COMPARATOR
Intervention: Starch (placebo)
Number of subjects: 40
Study 34015024 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult working conditions
Number of subjects: 25
Study 34015024 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcing factors
Number of subjects: 25
Study 34015024 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived risks
Number of subjects: 25
Study 32191729 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized CarePlus Wrap
Number of subjects: 301
Study 32191729 — intervention group
Group type: COMPARATOR
Intervention: Traditional chitenje
Number of subjects: 301
Study 35904063 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral carvedilol 5 mg bid (twice per day)
Number of subjects: 156
Study 35904063 — intervention group
Group type: COMPARATOR
Intervention: Topical brimonidine
Number of subjects: 156
Study 34297363 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic inulin‐type fructans (ITF) 16 g/d
Number of subjects: 29
Study 34297363 — intervention group
Group type: COMPARATOR
Intervention: Control supplement (maltodextrin) 16 g/d
Number of subjects: 29
Study 32684359 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed motivational messaging screening reminder letter with an option to call and request a free at-home fecal immunochemical screening test
Number of subjects: 7812
Study 32684359 — intervention group
Group type: COMPARATOR
Intervention: Standard invitation letter detailing that the individual was due for screening (control)
Number of subjects: 7812
Study 32684359 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed motivational messaging screening reminder letter
Number of subjects: 7812
Study 32684359 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal immunochemical test kits mailed to participants
Number of subjects: 7812
Study 35277023 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous enteral feeding
Number of subjects: 99
Study 35277023 — intervention group
Group type: COMPARATOR
Intervention: Intermittent enteral feeding
Number of subjects: 99
Study 32910077 — intervention group
Group type: EXPERIMENTAL
Intervention: Pessary use for more than 1 year
Number of subjects: 132
Study 32562889 — intervention group
Group type: EXPERIMENTAL
Intervention: Baveno VI criteria (B6C)
Number of subjects: 2368
Study 32562889 — intervention group
Group type: EXPERIMENTAL
Intervention: ANTICIPATE score
Number of subjects: 2368
Study 32562889 — intervention group
Group type: EXPERIMENTAL
Intervention: VariScreen
Number of subjects: 2368
Study 32562889 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded Baveno VI criteria (EB6C)
Number of subjects: 2368
Study 32562889 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall strategy
Number of subjects: 2368
Study 33132094 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitmore stem implantation in female patients
Number of subjects: 57
Study 33132094 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitmore stem implantation in male patients
Number of subjects: 57
Study 34558200 — intervention group
Group type: COMPARATOR
Intervention: Milvexian (4, 20, 60, 200, 300, or 500 mg)
Number of subjects: 104
Study 34558200 — intervention group
Group type: COMPARATOR
Intervention: Milvexian (once- or twice-daily for 14 days)
Number of subjects: 104
Study 34558200 — intervention group
Group type: COMPARATOR
Intervention: Milvexian (various doses)
Number of subjects: 104
Study 34558200 — intervention group
Group type: COMPARATOR
Intervention: Milvexian (200 and 500 mg)
Number of subjects: 104
Study 34728476 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily)
Number of subjects: 203
Study 34728476 — intervention group
Group type: COMPARATOR
Intervention: Placebo (metered dose inhaler and nasal saline)
Number of subjects: 203
Study 36116516 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose quadruple combination therapy
Number of subjects: 0
Study 36116516 — intervention group
Group type: COMPARATOR
Intervention: Standard dose monotherapy
Number of subjects: 0
Study 32412358 — intervention group
Group type: EXPERIMENTAL
Intervention: EnXtra®
Number of subjects: 0
Study 32412358 — intervention group
Group type: EXPERIMENTAL
Intervention: EnXtra® plus caffeine
Number of subjects: 0
Study 32412358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36011685 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential learning
Number of subjects: 48
Study 36011685 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-controlled feedback
Number of subjects: 48
Study 36011685 — intervention group
Group type: EXPERIMENTAL
Intervention: External focus of attention
Number of subjects: 48
Study 36011685 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 32151512 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided video reflection
Number of subjects: 37
Study 32151512 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulated learning
Number of subjects: 37
Study 32151512 — intervention group
Group type: COMPARATOR
Intervention: Experts (control group)
Number of subjects: 37
Study 35478433 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (6 weeks)
Number of subjects: 59
Study 35478433 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (2 weeks)
Number of subjects: 59
Study 35478433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 33331916 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly oral azithromycin for 48 weeks
Number of subjects: 347
Study 33331916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study 35331020 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache disorders (Migraine, tension-type headache, other headache)
Number of subjects: 1923
Study 35331020 — intervention group
Group type: COMPARATOR
Intervention: Sleep disturbances
Number of subjects: 1923
Study 35331020 — intervention group
Group type: COMPARATOR
Intervention: Alcohol consumption
Number of subjects: 1923
Study 35331020 — intervention group
Group type: COMPARATOR
Intervention: Low physical activity
Number of subjects: 1923
Study 35331020 — intervention group
Group type: COMPARATOR
Intervention: High screen time exposure
Number of subjects: 1923
Study 33007106 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and DHEA (n=19)
Number of subjects: 35
Study 33007106 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D (n=16)
Number of subjects: 35
Study 37706604 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided online psychological intervention for dysfunctional worry
Number of subjects: 670
Study 33676370 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical students
Number of subjects: 220
Study 33676370 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 220
Study 33676370 — intervention group
Group type: COMPARATOR
Intervention: Overall performance of primary reviewers
Number of subjects: 220
Study 33676370 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adverse events identified
Number of subjects: 220
Study 35970660 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing visits by operating room nurses (experimental group)
Number of subjects: 135
Study 35970660 — intervention group
Group type: COMPARATOR
Intervention: Nursing visits by service nurses (control group)
Number of subjects: 135
Study 33121891 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated whole breast irradiation (HWBI) - 40.5 Gy whole breast, 48.0 Gy to surgical bed, 15 fractions over 3 weeks
Number of subjects: 172
Study 33121891 — intervention group
Group type: COMPARATOR
Intervention: Accelerated partial breast irradiation (APBI) - 30 Gy delivered in 5 fractions of 6 Gy given on alternate days on the surgical bed
Number of subjects: 172
Study 33160977 — intervention group
Group type: EXPERIMENTAL
Intervention: 2019 ASGE guidelines
Number of subjects: 744
Study 33160977 — intervention group
Group type: COMPARATOR
Intervention: 2010 ASGE guidelines
Number of subjects: 744
Study 35948376 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) sessions, two times per week during scheduled specialist support classes.
Number of subjects: 300
Study 35948376 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (no intervention).
Number of subjects: 300
Study 33963489 — intervention group
Group type: EXPERIMENTAL
Intervention: FOCUS-EC
Number of subjects: 194
Study 33963489 — intervention group
Group type: COMPARATOR
Intervention: Online education
Number of subjects: 194
Study 32843284 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot application
Number of subjects: 90
Study 32843284 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold application
Number of subjects: 90
Study 32843284 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 36247425 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin and Ramipril (D+R)
Number of subjects: 33
Study 36247425 — intervention group
Group type: COMPARATOR
Intervention: Ramipril (R)
Number of subjects: 33
Study 33377992 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral parotid sparing IMRT
Number of subjects: 138
Study 33377992 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral parotid sparing IMRT
Number of subjects: 138
Study 33377992 — intervention group
Group type: COMPARATOR
Intervention: Both unilateral and bilateral parotid sparing IMRT
Number of subjects: 138
Study 35512954 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial bone marrow-derived hematopoietic progenitor cells (BMCs)
Number of subjects: 78
Study 35512954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 32171328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - Structured Material for Therapy (SMART), 6-week intervention
Number of subjects: 163
Study 32171328 — intervention group
Group type: COMPARATOR
Intervention: Waiting List Control (WLC)
Number of subjects: 163
Study 32171328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - SMART
Number of subjects: 163
Study 36238978 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian misalignment (CM) with delayed mealtimes (1:00 pm–11:00 pm)
Number of subjects: 7
Study 36238978 — intervention group
Group type: COMPARATOR
Intervention: Circadian alignment (CA) with mealtimes (9:00 am–7:00 pm)
Number of subjects: 7
Study 35500966 — intervention group
Group type: EXPERIMENTAL
Intervention: PILATES
Number of subjects: 22
Study 35500966 — intervention group
Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 22
Study 35360924 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic ECV using specific models in the validation group
Number of subjects: 1101
Study 35360924 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic ECV using common models in the validation group
Number of subjects: 1101
Study 35360924 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic ECV in the anemia cohort using specific model
Number of subjects: 1101
Study 34292205 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tcVNS stimulation
Number of subjects: 22
Study 34292205 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 22
Study 35650629 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate online assessment and subsequent sector-independent treatment coordination (ASSIST)
Number of subjects: 400
Study 35650629 — intervention group
Group type: COMPARATOR
Intervention: Usual care (waitlist group)
Number of subjects: 400
Study 32608096 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training with video modelling (22 sessions)
Number of subjects: 67
Study 32608096 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard community treatment)
Number of subjects: 67
Study 35803894 — intervention group
Group type: COMPARATOR
Intervention: Internet-based cognitive behavioural therapy (ICBT)
Number of subjects: 272
Study 35803894 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based psychodynamic therapy (IPDT)
Number of subjects: 272
Study 35803894 — intervention group
Group type: EXPERIMENTAL
Intervention: IPDT
Number of subjects: 272
Study 35803894 — intervention group
Group type: COMPARATOR
Intervention: ICBT
Number of subjects: 272
Study 35803894 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 272